Role of putrescine in interleukin 1 beta production in human histiocytic lymphoma cell line U937.
Treatment with 12-O-tetradecanoyl-phorbol-13-acetate (TPA) and incubation with lipopolysaccharide (LPS) induces interleukin 1 beta (IL-1 beta) production in the histiocytic lymphoma cell line U937. Here we investigated the effect of treatment with both TPA and 1 alpha, 25-dihydroxyvitamin D3 (1,25(OH)2D3) on LPS-induced IL-1 beta production in U937 cells. To clarify the mechanism of IL-1 beta production, the possible role of polyamines in this process was examined. Combined treatment with TPA and 1,25(OH)2D3 for 72 h followed by incubation with LPS for 24 h caused synergistic induction of both IL-1 beta release and mRNA expression. On the other hand, TPA increased the numbers of vitamin D3 receptors, which may be one mechanism of this synergistic induction. Ornithine decarboxylase (ODC), a rate-limiting enzyme for polyamine biosynthesis, was also induced by these compounds biphasically: the first peak of ODC activity was observed at 4 h of the incubation with the two compounds and the second peak was at 4 h after the addition of LPS. To find whether these peaks were related to IL-1 beta production, DL-alpha-difluoromethylornithine (DFMO), a specific irreversible inhibitor of ODC, was added together with TPA and 1,25(OH)2D3. DFMO decreased the cellular levels of putrescine and spermidine and suppressed IL-1 beta release and IL-1 beta mRNA expression by 65%. Exogenous putrescine, but not spermidine, abrogated these kinds of inhibition. Similar results were obtained with DFMO and the polyamines during the differentiation of the cells up to the monocyte or macrophage stage. These results thus suggest that changes in either of these intracellular polyamines, especially putrescine, help to regulate the differentiation of U937 cells, resulting in partial control of the regulation of IL-1 beta production.
Tahara
H
H
Department of Biochemistry, Osaka City University Medical School, Japan.
Otani
S
S
Matsui-Yuasa
I
I
Koyama
H
H
Nishizawa
Y
Y
Morisawa
S
S
Morii
H
H
D002117:Calcitriol / Q000494:pharmacology; D002454:Cell Differentiation; D002455:Cell Division; D000518:Eflornithine / Q000494:pharmacology; D006801:Humans; D007375:Interleukin-1 / Q000096:biosynthesis*; D007700:Kinetics; D008070:Lipopolysaccharides / Q000494:pharmacology; D016403:Lymphoma, Large B-Cell, Diffuse; D009000:Monocytes / Q000166:cytology / Q000378:metabolism*; D009955:Ornithine Decarboxylase / Q000378:metabolism; D065108:Ornithine Decarboxylase Inhibitors; D011700:Putrescine / Q000502:physiology*; D013095:Spermidine / Q000378:metabolism; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D007375:Interleukin-1; D008070:Lipopolysaccharides; D065108:Ornithine Decarboxylase Inhibitors; D009955:Ornithine Decarboxylase; D002117:Calcitriol; D013755:Tetradecanoylphorbol Acetate; D013095:Spermidine; D011700:Putrescine; D000518:Eflornithine